Elegrobart Phase 3 REVEAL-2 meets primary endpoint; proptosis responder rate 50-54% vs 15% placebo (p<0.0001)

Viridian Therapeutics, Inc.\DE

Proptosis responder rate at week 24: 50% (Q4W) and 54% (Q8W) vs 15% placebo; both p<0.0001.
Diplopia responder rate 61% (Q4W) vs 38% placebo (p=0.0118); complete resolution 44% vs 25% (p=0.0295).
Elegrobart well tolerated; 91% completed treatment, no treatment-related SAEs, low hearing impairment rates.
BLA submission for elegrobart on track for Q1 2027; veligrotug PDUFA target action date June 30, 2026.
Second positive Phase 3 trial for elegrobart; supports potential first subcutaneous autoinjector for TED.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.